Nifurtimox is a nitrofurane derivative used to treat diseases caused by trypanosomes. Nifurtimox was discovered empirically and its mechanism of action is unclear. It is believed that nifurtimox exerts its biological activity through the bioreduction of the nitro-group to a nitro-anion radical which undergoes redox-cycling with molecular oxygen.
| Molecular Weight | 287.29 |
| Formula | C10H13N3O5S |
| CAS Number | 23256-30-6 |
| Form | Solid |
| Solubility (25°C) | DMSO: ≥13 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] R Thakare, et al. Update on nifurtimox for treatment of Chagas disease
[2] No authors listed. Am J Health Syst Pharm. Nifurtimox
| Related Parasite Products |
|---|
| Argifin
Argifin is a sub-nanomolar chitinase inhibitor produced by soil microorganisms. |
| Argadin
Argadin is a cyclopentapeptide chitinase inhibitor. |
| DABCYL-Glu-Arg-Nle-Phe-Leu-Ser-Phe-Pro-EDANS
DABCYL-Glu-Arg-Nle-Phe-Leu-Ser-Phe-Pro-EDANS is a fluorescent dye, and can be applied in a fluorogenic substrate for an aspartyl proteinase from human malaria parasite. |
| Xenopsin precursor fragment
Xenopsin precursor fragment is an antimicrobial peptide, and has antibacterial/antifungal (10-500 μg/mL) and anti-protozoal (MIC: 2-20 μg/mL) activity. |
| Dihydrocyclosporin A
Dihydrocyclosporin A is a derivative of Cyclosporine A. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
